Histone deacetylase 1: a target of 9-hydroxystearic acid in the inhibition of cell growth in human colon cancer

被引:40
作者
Calonghi, N [1 ]
Cappadone, C
Pagnotta, E
Boga, C
Bertucci, C
Fiori, J
Tasco, G
Casadio, R
Masotti, L
机构
[1] Univ Bologna, Dept Biochem G Moruzzi, Bologna, Italy
[2] Univ Bologna, Dept Organ Chem A Mangini, Bologna, Italy
[3] Univ Bologna, Dept Pharmaceut Sci, I-40126 Bologna, Italy
[4] Univ Bologna, Ctr Interdipartimentale Ric Biotecnol, Lab Biocomp, I-40126 Bologna, Italy
关键词
endogenous lipid peroxidation products; tumor; mass spectrometry; computational modeling;
D O I
10.1194/jlr.M400424-JLR200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
lipoperoxidation product, 9-hydroxystearic acid (9-HSA), acts in colon carcinoma cells (HT29) as a growth inhibitor by inducing p21(WAF1) in an immediate-early, p53-independent manner and that p21(WAF1) is required for 9-HSA-mediated growth arrest in HT29 cells. It is conceivable, therefore, to hypothesize that the cytostatic effect induced by this agent is at least partially associated with a molecular mechanism that involves histone deacetylase 1 (HDAC1) inhibition, as demonstrated for sodium butyrate and other specific inhibitors, such as trichostatin A and hydroxamic acids. Here, we show that, after administration, 9-HSA causes an accumulation of hyperacetylated histones and strongly inhibits the activity of HDAC1. The interaction of 9-HSA with the catalytic site of the enzyme has been highlighted by computational modeling of the human HDAC1, using its homolog from the hyperthermophilic Aquifex aeolicus as a template. Consistent with the experimental data, we find that 9-HSA can bind to the active site of the protein, showing that the inhibition of the enzyme can be explained at the molecular level by the ligand-protein interaction.
引用
收藏
页码:1596 / 1603
页数:8
相关论文
共 23 条
[1]   The retinoblastoma gene product is reversibly dephosphorylated and bound in the nucleus in S and G(2) phases during hypoxic stress [J].
Amellem, O ;
Stokke, T ;
Sandvik, JA ;
Pettersen, EO .
EXPERIMENTAL CELL RESEARCH, 1996, 227 (01) :106-115
[2]   Gas chromatography/mass spectrometric assay of endogenous cellular lipid peroxidation products: quantitative analysis of 9- and 10-hydroxystearic acids [J].
Bertucci, C ;
Hudaib, M ;
Boga, C ;
Calonghi, N ;
Cappadone, C ;
Masotti, L .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2002, 16 (09) :859-864
[3]   9-hydroxystearic acid upregulates p21WAF1 in HT29 cancer cells [J].
Calonghi, N ;
Cappadone, C ;
Pagnotta, E ;
Farruggia, G ;
Buontempo, F ;
Boga, C ;
Brusa, GL ;
Santucci, MA ;
Masotti, L .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 314 (01) :138-142
[4]   PHASE PROPERTIES OF MIXTURES OF 9- AND 10-OXO-OCTADECANOIC ACIDS AND OF 9- AND 10-HYDROXYOCTADECANOIC ACIDS [J].
COCHRANE, CC ;
HARWOOD, HJ .
JOURNAL OF ORGANIC CHEMISTRY, 1961, 26 (04) :1278-+
[5]   Inhibition of histone deacetylase activity by butyrate [J].
Davie, JR .
JOURNAL OF NUTRITION, 2003, 133 (07) :2485S-2493S
[6]   Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors [J].
Finnin M.S. ;
Donigian J.R. ;
Cohen A. ;
Richon V.M. ;
Rifkind R.A. ;
Marks P.A. ;
Breslow R. ;
Pavletich N.P. .
Nature, 1999, 401 (6749) :188-193
[7]   The emerging role of class II histone deacetylases [J].
Fischle, W ;
Kiermer, V ;
Dequiedt, F ;
Verdin, E .
BIOCHEMISTRY AND CELL BIOLOGY, 2001, 79 (03) :337-348
[8]  
FOLCH J, 1957, J BIOL CHEM, V226, P497
[9]   Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer [J].
Johnstone, RW .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :287-299
[10]   Functional significance of histone deacetylase diversity [J].
Khochbin, S ;
Verdel, A ;
Lemercier, C ;
Seigneurin-Berny, D .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2001, 11 (02) :162-166